作者
María Julia Montoro,Laura Palomo,Claudia Haferlach,Pamela Acha,Onyee Chan,Víctor Navarro,Yasuo Kubota,Felicitas Schulz,Manja Meggendorfer,Robert Briski,Najla Al-Ali,Blanca Xicoy,Félix López,Francesc Bosch,Teresa González,Lea Naomi Eder,Andrés Jerez,Yu‐Hung Wang,Alessia Campagna,Valeria Santini,Teresa Bernal,Esperanza Such,Wen‐Chien Chou,Nicolás Díaz Varela,Uwe Platzbecker,Detlef Haase,María Diez‐Campelo,Matteo Giovanni Della Porta,Hussain I. Saba,Daniel H. Wiseman,Ulrich Germing,Jarosław P. Maciejewski,Rami S. Komrokji,Françesc Solé,Torsten Haferlach,David Valcárcel
摘要
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, while the remaining patients displayed monoallelic mutations. TP53 multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53 monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53 monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53 multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q).